Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.

about

Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.

Item

http://www.wikidata.org/entity/Q36438206

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Autopsy Analysis may Contribut ...... imary Malignancies in Myeloma.

@ast

Autopsy Analysis may Contribut ...... imary Malignancies in Myeloma.

@en

type

Item

label

Autopsy Analysis may Contribut ...... imary Malignancies in Myeloma.

@ast

Autopsy Analysis may Contribut ...... imary Malignancies in Myeloma.

@en

prefLabel

Autopsy Analysis may Contribut ...... imary Malignancies in Myeloma.

@ast

Autopsy Analysis may Contribut ...... imary Malignancies in Myeloma.

@en

P1476

Autopsy Analysis may Contribut ...... imary Malignancies in Myeloma.

@en

P2093

Akiyoshi Miwa

http://www.w3.org/2001/XMLSchema#string

Junichiro Takano

http://www.w3.org/2001/XMLSchema#string

Shotaro Hagiwara

http://www.w3.org/2001/XMLSchema#string

P2860

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Lenalidomide after stem-cell transplantation for multiple myeloma

Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults

Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms.

MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

P304

5949

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4081/RT.2015.5949

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288872344

http://www.w3.org/2001/XMLSchema#string

P698

26788269

http://www.w3.org/2001/XMLSchema#string

P921

autopsy

P932

4703915

http://www.w3.org/2001/XMLSchema#string